Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Summary

This is Phase 2, open label, non randomized single arm study to determine whether the administration of vactosertib with durvalumab will provide meaningful increases in the Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a response with anti-PD-1/PD-L1 based regimens

Timeline

Start

2019-12-13

Primary completion

2023-12-30

Completion

2024-12-30

Drugs

Indications